Key facts
- Nuclide Therapeutics’s last known valuation is $19.6M (Sep 2025).
- It has raised $6.8M; the latest was Seed Round ($6.8M) in Sep 2025.
- Notable investors include King's College London, Marathon Beteiligungs.
- Status: Privately Held (backing).
- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for Nuclide Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for Nuclide Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Nuclide Therapeutics
Developer of targeted radiopharmaceutical therapies designed for oncology applications. The company combines nuclear medicine with biotechnology to identify and treat resistant cancer types, leveraging novel biomarkers, precision isotopes, and advanced molecular targeting, enabling clinical researchers and oncologists to pursue more effective treatment options for patients with limited therapeutic alternatives.
- Sector
- Healthcare
- HQ
- London, United Kingdom
- Founded
- 2024
- Employees
- 4
- Website
- nuclidetx.com/
- Ownership
- Privately Held (backing)
Nuclide Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Nuclide Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Nuclide Therapeutics in its N-PORT filings yet. We sweep new filings monthly.